QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Lung function (FEV₁) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Time to first moderate or severe exacerbation All participants · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).
1 finding from 1 review
Lung function (FEV₁) Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring emergency department treatment or admission · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations All… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in SGRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes dry eye symptoms, measured using the SPEED score at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
MD 0
Studies not reported
Very low
Incidence of adverse events at 3 months of · people with meibomian gland dysfunction
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Clinical signs—TBUT at 1 month (seconds) · people with meibomian gland dysfunction
IPL (with/without MGX) showed no clear difference in sodium fluorescein TBUT, measured in seconds, at 3 months of compared with sham or no treatment (with/without MGX) (low certainty).
1 finding from 1 review
MD 2.02
Studies not reported
Low
NIBUT, measured in seconds, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes NIBUT, measured in seconds, at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
MD 5.5
Studies not reported
Very low
Tear osmolarity, measured in mOsmol/L, at 3 months of · people with meibomian gland dysfunction
IPL (with/without MGX) showed no clear difference in tear osmolarity, measured in mOsmol/L, at 3 months of compared with sham or no treatment (with/without MGX) (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Meibomian gland orifice plugging, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes meibomian gland orifice plugging, at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Corneal sodium fluorescein staining, measured using a validated clinical scale, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes corneal sodium fluorescein staining, measured using a validated… compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Clinical and radiographic success
1 finding from 1 review
no estimate extracted
1 study
GRADE not reported
Intervention not reported
Calcific metamorphosis (adverse event)
1 finding from 1 review
no estimate extracted
1 study
GRADE not reported
Outcomes* · chronic bronchitis or COPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with no exacerbations in study period · chronic bronchitis or COPD
Mucolytic probably leads to higher participants with no exacerbations in study period compared with placebo (moderate certainty).
1 finding from 1 review